Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1801]

HER2DX assay and survival outcomes: An individual-patient level meta-analysis...

Dr Guillermo Villacampa - Vall d'Hebron Institute of Oncology (VHIO)...

HER2DX assay and survival outcomes: An individual-patient level meta-analysis of 2,031 patients with HER2-positive BC ( Dr Guillermo Villacampa - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain )

Blood test may identify patients with non-small cell lung cancer subtype who...

Dr Pasi A. Jänne - Dana-Farber Cancer Institute, Boston, USA

Blood test may identify patients with non-small cell lung cancer subtype who can benefit from combination therapy ( Dr Pasi A. Jänne - Dana-Farber Cancer Institute, Boston, USA )

Urinary markers in the surveillance setting of non-muscle invasive bladder...

Dr Thomas Dreyer - Aarhus University Hospital, Aarhus, Denmark

Urinary markers in the surveillance setting of non-muscle invasive bladder cancer ( Dr Thomas Dreyer - Aarhus University Hospital, Aarhus, Denmark )

Chemo-immunotherapy combo nivolumab and nab-paclitaxel could be effective...

Dr Chiara Mercinelli - San Raffaele Scientific Institute, Milan, Italy

Chemo-immunotherapy combo nivolumab and nab-paclitaxel could be effective perioperative strategy for MIBC ( Dr Chiara Mercinelli - San Raffaele Scientific Institute, Milan, Italy )

EAU 2024: Bladder cancer latest

Dr Bernadett Szabados, Dr Félix Guerrero-Ramos, Dr Yohann Loriot, Prof Andrea...

EAU 2024: Bladder cancer latest ( Dr Bernadett Szabados, Dr Félix Guerrero-Ramos, Dr Yohann Loriot, Prof Andrea Necchi and Dr Cosimo De Nunzio )

Addressing new treatment opportunities in localised bladder cancer

Dr Benjamin Pradere, Prof Paolo Gontero and Dr Carmen Mir

Addressing new treatment opportunities in localised bladder cancer ( Dr Benjamin Pradere, Prof Paolo Gontero and Dr Carmen Mir )

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus

Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale...

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus ( Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini )

Nab-paclitaxel as first line treatment of gastrointestinal neuroendocrine...

Dr Lorraine Chantrill - University of Sydney, Sydney, Australia

Nab-paclitaxel as first line treatment of gastrointestinal neuroendocrine carcinomas shows efficacious results ( Dr Lorraine Chantrill - University of Sydney, Sydney, Australia )

Trifluridine/tipiracil and bevacizumab combination gives a prolonged PFS...

Prof Hironaga Satake - Kochi Medical School, Kochi, Japan

Trifluridine/tipiracil and bevacizumab combination gives a prolonged PFS compared to trifluridine/tipiracil monotherapy in mCRC ( Prof Hironaga Satake - Kochi Medical School, Kochi, Japan )

Enfortumab vedotin in combination with pembrolizumab is a potential new...

Dr Michiel Simon Van Der Heijden - Netherlands Cancer Institute, Amsterdam...

Enfortumab vedotin in combination with pembrolizumab is a potential new standard of care for 1L la/mUC ( Dr Michiel Simon Van Der Heijden - Netherlands Cancer Institute, Amsterdam, Netherlands )

What's new on ADCs in management of advanced NSCLC

Dr David Planchard - Institute Gustave Roussy, Villejuif, France

What's new on ADCs in management of advanced NSCLC ( Dr David Planchard - Institute Gustave Roussy, Villejuif, France )

Treatment of metastatic NSCLC without PD-L1 expression and without oncogene...

Dr Antonio Passaro - European Institute of Oncology, Milan, Italy

Treatment of metastatic NSCLC without PD-L1 expression and without oncogene addiction ( Dr Antonio Passaro - European Institute of Oncology, Milan, Italy )

More from ecancer